TOP2A amplification was once considered a potential marker for anthracycline exemption in early breast cancer; however, the READ study, through a large prospective cohort, confirmed that TOP2A amplification did not effectively identify breast cancer patients who could achieve equivalent overall survival outcomes without anthracycline treatment [11, 12], underscoring the unmet need for reliable predictive biomarkers for anthracycline exemption in postoperative TNBC treatment. This evidence concerns the gene TOP2A and breast carcinoma.